## Keith A Rodvold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5841672/publications.pdf

Version: 2024-02-01

93 papers 5,770 citations

33 h-index 76900 74 g-index

94 all docs 94 docs citations 94 times ranked 5935 citing authors

| #  | Article   | IF                | CITATIONS             |
|----|---|-------------------|-----------------------|
| 1  | Diagnosis and Management of Complicated Intra-abdominal Infection in Adults and Children:<br>Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clinical<br>Infectious Diseases, 2010, 50, 133-164. | 5.8               | 1,260                 |
| 2  | Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surgical Infections, 2010, 11, 79-109.                 | 1.4               | 401                   |
| 3  | Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future. Clinical Infectious Diseases, 2014, 58, S20-S27.  | 5.8               | 279                   |
| 4  | Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. Journal of Antimicrobial Chemotherapy, 2006, 58, 1221-1229.  | 3.0               | 272                   |
| 5  | Innovative approaches to optimizing the delivery of vancomycin in individual patients. Advanced Drug<br>Delivery Reviews, 2014, 77, 50-57.  | 13.7              | 215                   |
| 6  | Penetration of Anti-Infective Agents into Pulmonary Epithelial Lining Fluid. Clinical Pharmacokinetics, 2011, 50, 637-664.  | 3.5               | 190                   |
| 7  | Clinical Pharmacokinetics of Clarithromycin. Clinical Pharmacokinetics, 1999, 37, 385-398.  | 3.5               | 187                   |
| 8  | Steady-State Plasma and Intrapulmonary Concentrations of Levofloxacin and Ciprofloxacin in Healthy Adult Subjects. Chest, 2001, 119, 1114-1122.   | 0.8               | 156                   |
| 9  | Antimicrobial Dosing in Obese Patients. Clinical Infectious Diseases, 1997, 25, 112-118.  | 5.8               | 151                   |
| 10 | The Infectious Diseases Society of America $\hat{a} \in \mathbb{N}$ 10 $\tilde{A}$ — $\hat{a} \in \mathbb{N}$ 20 Initiative (10 New Systemic Antibacterial Agents 2019, 69, 1-11.   | US) Tj ET0<br>5.8 | Qq0 0 0 rgBT /<br>120 |
| 11 | Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects. Journal of Antimicrobial Chemotherapy, 2012, 67, 2463-2469.   | 3.0               | 108                   |
| 12 | National Survey of Extended-Interval Aminoglycoside Dosing. Clinical Infectious Diseases, 2000, 30, 433-439.  | 5.8               | 105                   |
| 13 | Steady-State Plasma and Bronchopulmonary Concentrations of Intravenous Levofloxacin and Azithromycin in Healthy Adults. Antimicrobial Agents and Chemotherapy, 2003, 47, 2450-2457.   | 3.2               | 102                   |
| 14 | Dosage Adjustments for Antibacterials in Obese Patients. Clinical Pharmacokinetics, 2000, 38, 415-426.  | 3.5               | 101                   |
| 15 | Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 7232-7239.  | 3.2               | 88                    |
| 16 | Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2017, 61, .  | 3.2               | 86                    |
| 17 | Pharmacokinetics and Pharmacodynamics of Fluoroquinolones. Pharmacotherapy, 2001, 21, 233S-252S.  | 2.6               | 85                    |
| 18 | Renal Dosing of Antibiotics: Are We Jumping the Gun?. Clinical Infectious Diseases, 2019, 68, 1596-1602.  | 5.8               | 85                    |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Pharmacokinetics and Administration Regimens of Vancomycin in Neonates, Infants and Children. Clinical Pharmacokinetics, 1997, 33, 32-51.   | 3.5 | 84        |
| 20 | Daptomycin: A novel cyclic lipopeptide antimicrobial. American Journal of Health-System Pharmacy, 2005, 62, 1145-1158.  | 1.0 | 72        |
| 21 | Penetration of Anti-Infective Agents into PulmonaryEpithelial Lining Fluid. Clinical Pharmacokinetics, 2011, 50, 689-704.   | 3.5 | 68        |
| 22 | Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole. Antimicrobial Agents and Chemotherapy, 2009, 53, 3294-3301.   | 3.2 | 64        |
| 23 | New Oral Macrolide and Fluoroquinolone Antibiotics: An Overview of Pharmacokinetics, Interactions, and Safety. Clinical Infectious Diseases, 1993, 17, S192-S199.                                       | 5.8 | 61        |
| 24 | Tigecycline: A Novel Broad-Spectrum Antimicrobial. Annals of Pharmacotherapy, 2007, 41, 965-972.  | 1.9 | 60        |
| 25 | Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung. Current Opinion in Pharmacology, 2017, 36, 114-123.                               | 3.5 | 59        |
| 26 | Antibiotic Drug Interactions. Medical Clinics of North America, 2006, 90, 1223-1255.  | 2.5 | 58        |
| 27 | Penetration of Vancomycin into Epithelial Lining Fluid in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2011, 55, 5507-5511.   | 3.2 | 51        |
| 28 | Comparison of Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Solithromycin (CEM-101) in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2012, 56, 5076-5081. | 3.2 | 49        |
| 29 | The role of carbapenems in the treatment of severe nosocomial respiratory tract infections. Expert Opinion on Pharmacotherapy, 2008, 9, 561-575.  | 1.8 | 46        |
| 30 | Safety and tolerability of fluoroquinolones. Clinical Cornerstone, 2003, 5, S29-S36.  | 0.7 | 44        |
| 31 | Population pharmacokinetic modeling and Monte Carlo simulation of varying doses of intravenous metronidazole. Diagnostic Microbiology and Infectious Disease, 2006, 55, 303-309.                        | 1.8 | 44        |
| 32 | An Updated Comparison of Drug Dosing Methods. Clinical Pharmacokinetics, 1991, 20, 463-476.   | 3.5 | 41        |
| 33 | Pharmacodynamics of Antiinfective Therapy: Taking What We Know to the Patient's Bedside. Pharmacotherapy, 2001, 21, 319S-330S.  | 2.6 | 36        |
| 34 | Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam following Intravenous Administration of ETX2514SUL to Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2018, 62, .      | 3.2 | 35        |
| 35 | Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline. Clinical Infectious Diseases, 2019, 69, S16-S22.  | 5.8 | 34        |
| 36 | Bayesian Forecasting of Serum Vancomycin Concentrations in Neonates and Infants. Therapeutic Drug Monitoring, 1995, 17, 239-246.  | 2.0 | 33        |

3

| #  | Article   | IF  | Citations |
|----|---|-----|-----------|
| 37 | An Updated Comparison of Drug Dosing Methods. Clinical Pharmacokinetics, 1991, 20, 374-388.   | 3.5 | 32        |
| 38 | Sex-Related Differences in the Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsules<br>Boosted with Low-Dose Ritonavir in Patients Infected with Human Immunodeficiency Virus Type 1.<br>Pharmacotherapy, 2004, 24, 592-599. | 2.6 | 32        |
| 39 | Pharmacokinetics and Dialytic Clearance of Ceftazidime-Avibactam in a Critically Ill Patient on Continuous Venovenous Hemofiltration. Antimicrobial Agents and Chemotherapy, 2017, 61, .  | 3.2 | 32        |
| 40 | Polymyxin Susceptibility Testing and Interpretive Breakpoints: Recommendations from the United States Committee on Antimicrobial Susceptibility Testing (USCAST). Antimicrobial Agents and Chemotherapy, 2020, 64, .                    | 3.2 | 32        |
| 41 | Therapeutic Drug Monitoring of Vancomycin in a Morbidly Obese Patient. Therapeutic Drug Monitoring, 1998, 20, 261-265.  | 2.0 | 32        |
| 42 | Intrapulmonary pharmacokinetic profile of cefiderocol in mechanically ventilated patients with pneumonia. Journal of Antimicrobial Chemotherapy, 2021, 76, 2902-2905.   | 3.0 | 30        |
| 43 | Cost Considerations in Therapeutic Drug Monitoring of Aminoglycosides. Clinical Pharmacokinetics, 1994, 26, 71-81.  | 3.5 | 29        |
| 44 | Plasma and Intrapulmonary Concentrations of Cefepime and Zidebactam following Intravenous Administration of WCK 5222 to Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2018, 62, .                                      | 3.2 | 29        |
| 45 | Zanamivir Pharmacokinetics and Pulmonary Penetration into Epithelial Lining Fluid following<br>Intravenous or Oral Inhaled Administration to Healthy Adult Subjects. Antimicrobial Agents and<br>Chemotherapy, 2011, 55, 5178-5184.     | 3.2 | 28        |
| 46 | Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2015, 59, 3956-3965.  | 3.2 | 27        |
| 47 | Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update. Clinical Pharmacokinetics, 2022, 61, 17-46.  | 3.5 | 26        |
| 48 | Pharmacokinetics and Pharmacodynamics of Intravenous Levofloxacin at 750 Milligrams and Various Doses of Metronidazole in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2004, 48, 4597-4605.                           | 3.2 | 25        |
| 49 | Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk-Zaske dosing method revisited in the era of obesity. Diagnostic Microbiology and Infectious Disease, 2014, 78, 178-187.                      | 1.8 | 25        |
| 50 | Pharmacokinetics, pharmacodynamics, and safety of <scp>USL</scp> 261, a midazolam formulation optimized for intranasal delivery, in a randomized study with healthy volunteers. Epilepsia, 2015, 56, 1723-1731.                         | 5.1 | 25        |
| 51 | Telavancin: The Long and Winding Road From Discovery to Food and Drug Administration Approvals and Future Directions. Clinical Infectious Diseases, 2015, 61, S38-S47.  | 5.8 | 25        |
| 52 | Phase I Study To Evaluate the Pharmacokinetics, Safety, and Tolerability of Two Dosing Regimens of Oral Fosfomycin Tromethamine in Healthy Adult Participants. Antimicrobial Agents and Chemotherapy, 2018, 62, .                       | 3.2 | 24        |
| 53 | Steady-state plasma and bronchopulmonary characteristics of clarithromycin extended-release tablets in normal healthy adult subjects. Journal of Antimicrobial Chemotherapy, 2003, 52, 450-456.   | 3.0 | 23        |
| 54 | Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2018, 62, .  | 3.2 | 23        |

| #  | Article  | IF   | Citations |
|----|--|------|-----------|
| 55 | Pharmacokinetics of intravenous vancomycin in pediatric cardiopulmonary bypass surgery. Pediatric Infectious Disease Journal, 1993, 12, 300-303.   | 2.0  | 22        |
| 56 | Omadacycline: A Review of the Clinical Pharmacokinetics and Pharmacodynamics. Clinical Pharmacokinetics, 2020, 59, 409-425.  | 3.5  | 22        |
| 57 | Omadacycline: a novel aminomethylcycline. Infection and Drug Resistance, 2019, Volume 12, 1895-1915.   | 2.7  | 21        |
| 58 | Bayesian Forecasting of Serum Gentamicin Concentrations in Intensive Care Patients. Clinical Pharmacokinetics, 1990, 18, 409-418.  | 3.5  | 18        |
| 59 | Effects of six-week clarithromycin therapy in corticosteroid-dependent asthma: A randomized, double-blind, placebo-controlled pilot study. Current Therapeutic Research, 2004, 65, 1-12. | 1.2  | 18        |
| 60 | Pharmacokinetic evaluation of meropenem and vaborbactam for the treatment of urinary tract infection. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 1007-1021.             | 3.3  | 18        |
| 61 | Intrapulmonary Pharmacokinetics of GSK2251052 in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2013, 57, 3334-3339.   | 3.2  | 16        |
| 62 | Single daily doses of aminoglycosides. Lancet, The, 1997, 350, 1412.   | 13.7 | 15        |
| 63 | Comparison of Plasma and Intrapulmonary Concentrations of Nafithromycin (WCK 4873) in Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2017, 61, .                         | 3.2  | 15        |
| 64 | Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin. Journal of Antimicrobial Chemotherapy, 2019, 74, iii2-iii4.            | 3.0  | 14        |
| 65 | An Updated Comparison of Drug Dosing Methods. Clinical Pharmacokinetics, 1991, 20, 209-217.  | 3.5  | 13        |
| 66 | An Updated Comparison of Drug Dosing Methods. Clinical Pharmacokinetics, 1991, 20, 280-292.  | 3.5  | 12        |
| 67 | Phenobarbital Pharmacokinetics in Obesity. Clinical Pharmacokinetics, 1992, 22, 481-484.   | 3.5  | 12        |
| 68 | Variability in Telavancin Cross-Reactivity among Vancomycin Immunoassays. Antimicrobial Agents and Chemotherapy, 2014, 58, 7093-7097.  | 3.2  | 12        |
| 69 | Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 1741-1750.  | 3.3  | 11        |
| 70 | 60 Plus Years Later and We Are Still Trying to Learn How to Dose Vancomycin. Clinical Infectious Diseases, 2020, 70, 1546-1549.  | 5.8  | 11        |
| 71 | Methods of Minimising the Cost of Aminoglycoside Therapy to Hospitals. Pharmacoeconomics, 1993, 3, 228-243.  | 3.3  | 9         |
| 72 | National survey on continuous and extended infusions of antibiotics. American Journal of Health-System Pharmacy, 2012, 69, 1895-1904.  | 1.0  | 9         |

| #  | Article  | IF  | Citations |
|----|--|-----|-----------|
| 73 | Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage. Antimicrobial Agents and Chemotherapy, 2014, 58, 419-423.                               | 3.2 | 9         |
| 74 | Safety and Efficacy of Tigecycline to Treat Multidrug-resistant Infections in Pediatrics: An Evidence Synthesis. Pediatric Infectious Disease Journal, 2019, 38, 710-715.  | 2.0 | 9         |
| 75 | How Important Is Therapeutic Drug Monitoring in the Prediction and Avoidance of Adverse Reactions?. Drug Safety, 1995, 12, 359-363.  | 3.2 | 8         |
| 76 | Pharmacokinetics of Telavancin at Fixed Doses in Normal-Body-Weight and Obese (Classes I, II, and III) Adult Subjects. Antimicrobial Agents and Chemotherapy, 2018, 62, .  | 3.2 | 8         |
| 77 | ZTI-01 (fosfomycin for injection) in the treatment of hospitalized patients with complicated urinary tract infections. Future Microbiology, 2019, 14, 461-475.   | 2.0 | 6         |
| 78 | Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 463-472.  | 3.3 | 5         |
| 79 | A Pharmacometric Comparison of Omadacycline and Tigecycline Epithelial Lining Fluid (ELF)<br>Penetration. Open Forum Infectious Diseases, 2017, 4, S529-S530.  | 0.9 | 4         |
| 80 | 1311. Intrapulmonary Pharmacokinetics of Cefiderocol in Hospitalized and Ventilated Patients Receiving Standard of Care Antibiotics for Bacterial Pneumonia. Open Forum Infectious Diseases, 2020, 7, S668-S668. | 0.9 | 4         |
| 81 | Editorial Commentary: Improving Prescribers to Advance Antimicrobial Stewardship. Clinical Infectious Diseases, 2015, 60, 1259-1261.   | 5.8 | 3         |
| 82 | Plasma and Intrapulmonary Concentrations of Tebipenem following Oral Administration of Tebipenem Pivoxil Hydrobromide to Healthy Adult Subjects. Antimicrobial Agents and Chemotherapy, 2022, 66, .              | 3.2 | 3         |
| 83 | Prediction of Acetaminophen Concentrations in Overdose Patients Using a Bayesian Pharmacokinetic Model. Journal of Toxicology: Clinical Toxicology, 1994, 32, 17-30.   | 1.5 | 2         |
| 84 | IV Cefuroxime Plus Oral Clarithromycin or IV Erythromycin for the Treatment of Community-Acquired Pneumonia in Hospitalised Patients. Clinical Drug Investigation, 1997, 14, 23-34.                              | 2.2 | 2         |
| 85 | Stability and compatibility of levofloxacin and metronidazole during simulated and actual Y-site administration. American Journal of Health-System Pharmacy, 2005, 62, 88-92.                                    | 1.0 | 2         |
| 86 | Drug interactions involving anti-infective agents. , 2010, , 68-103.   |     | 2         |
| 87 | Clearance of ceftazidime-avibactam in an in vitro continuous venovenous hemodialysis model. Open Forum Infectious Diseases, 2017, 4, S294-S295.  | 0.9 | 2         |
| 88 | Collaborative Strategies for Improving Clinical Resource Utilization: How Pharmacists Can Make a Difference. Journal of Managed Care Pharmacy, 2009, 15, 10-14.  | 2.2 | 1         |
| 89 | Telavancin for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> Infections. Clinical Infectious Diseases, 2015, 61, S35-S37.  | 5.8 | 1         |
| 90 | START Learning by Sharing: FAQs. Journal of Managed Care Pharmacy, 2009, 15, 24-26.  | 2,2 | 1         |

| #  | Article   | IF  | CITATIONS |
|----|---|-----|-----------|
| 91 | Antibiotic Optimization: Concepts and Strategies in Clinical Practice Edited by Robert C. Owens, Jr., Paul G. Ambrose, and Charles H. Nightingale New York: Marcel Dekker, 2005. 663 pp., illustrated. \$179.95 (cloth). Clinical Infectious Diseases, 2005, 41, 1828-1828. | 5.8 | O         |
| 92 | Authors' Reply to De Sutter, De Waele, and Vermeulen: "Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update― Clinical Pharmacokinetics, 2022, 61, 337-338.   | 3.5 | O         |
| 93 | Journal of Managed Care Pharmacy. START (Stewardship Tactics for Antimicrobial Resistance Trends).<br>Introduction. Journal of Managed Care Pharmacy, 2009, 15, S3-4.   | 2.2 | 0         |